SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stephanie Mocilan who wrote ()5/6/1997 11:49:00 PM
From: harkenman   of 998
 
Even Cephalon officials don't believe in Myotrophin drug efficacy, want to do combination study with Rilutek, the only approved drug for ALs.
source: WSJ

Cephalon officials say they are willing to conduct another
study with Myotrophin as a treatment for ALS, but the
company wants to study a combination of Rilutek and
Myotrophin. Researchers and analysts believe that ultimately
patients will use both drugs. 'There is some pre-clinical
evidence to suggest that these drugs in combination are more
effective than as single agents,' Rubin says. 'If there were to be
a Phase IV study, it would likely be a combination study
looking at these two agents.'

E
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News